In Brief This Week: Bruker; Hologic, Immucor; Cancer Genetics; New England Biolabs; Genewiz; Genedata | GenomeWeb

NEW YORK (GenomeWeb News) – Investment bank Jefferies this week upgraded Bruker's stock to Buy from Hold and upped its price target on the stock from $20 to $25. "We have increased confidence in [Bruker's] intermediate-term profit and cash flow trajectories, and see more than [an] adequate degree of conservatism in its formal 2013 outlook," Jefferies analyst Jon Wood wrote in a note published Thursday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.